575 related articles for article (PubMed ID: 15126694)
1. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis.
Wyttenbach A
J Mol Neurosci; 2004; 23(1-2):69-96. PubMed ID: 15126694
[TBL] [Abstract][Full Text] [Related]
2. [Molecular biology of polyglutamine diseases].
Owecki M; Kozubski W
Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
[TBL] [Abstract][Full Text] [Related]
3. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.
Fu L; Gao YS; Sztul E
Neurobiol Dis; 2005 Dec; 20(3):656-65. PubMed ID: 15964198
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.
Reis SD; Pinho BR; Oliveira JMA
Mol Neurobiol; 2017 Oct; 54(8):5829-5854. PubMed ID: 27660272
[TBL] [Abstract][Full Text] [Related]
6. Role of molecular chaperones in neurodegenerative disorders.
Meriin AB; Sherman MY
Int J Hyperthermia; 2005 Aug; 21(5):403-19. PubMed ID: 16048838
[TBL] [Abstract][Full Text] [Related]
7. Polyglutamine disease proteins: Commonalities and differences in interaction profiles and pathological effects.
Bonsor M; Ammar O; Schnoegl S; Wanker EE; Silva Ramos E
Proteomics; 2024 Jun; 24(12-13):e2300114. PubMed ID: 38615323
[TBL] [Abstract][Full Text] [Related]
8. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation.
Schaffar G; Breuer P; Boteva R; Behrends C; Tzvetkov N; Strippel N; Sakahira H; Siegers K; Hayer-Hartl M; Hartl FU
Mol Cell; 2004 Jul; 15(1):95-105. PubMed ID: 15225551
[TBL] [Abstract][Full Text] [Related]
9. Heat shock proteins and neuroprotection.
Trivedi S
Recent Pat DNA Gene Seq; 2007; 1(2):134-7. PubMed ID: 19075927
[TBL] [Abstract][Full Text] [Related]
10. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
Nagai Y; Popiel HA
Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
[TBL] [Abstract][Full Text] [Related]
11. [The advances in research on phosphorylation of polyglutamine disease].
Zhou YF; Jiang H; Tang JG; Tang BS
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):414-7. PubMed ID: 18683139
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of chaperones on polyglutamine diseases.
Kobayashi Y; Sobue G
Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):165-8. PubMed ID: 11719246
[TBL] [Abstract][Full Text] [Related]
13. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.
Ross CA
Neuron; 2002 Aug; 35(5):819-22. PubMed ID: 12372277
[TBL] [Abstract][Full Text] [Related]
14. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
[TBL] [Abstract][Full Text] [Related]
15. The role of heat shock proteins as chaperones on several human diseases.
Mellati AA
Saudi Med J; 2006 Sep; 27(9):1302-5. PubMed ID: 16951762
[TBL] [Abstract][Full Text] [Related]
16. Current understanding on the pathogenesis of polyglutamine diseases.
He XH; Lin F; Qin ZH
Neurosci Bull; 2010 Jun; 26(3):247-56. PubMed ID: 20502504
[TBL] [Abstract][Full Text] [Related]
17. The Expanding Clinical Universe of Polyglutamine Disease.
Huang S; Zhu S; Li XJ; Li S
Neuroscientist; 2019 Oct; 25(5):512-520. PubMed ID: 30614396
[TBL] [Abstract][Full Text] [Related]
18. The small heat shock proteins, especially HspB4 and HspB5 are promising protectants in neurodegenerative diseases.
Zhu Z; Reiser G
Neurochem Int; 2018 May; 115():69-79. PubMed ID: 29425965
[TBL] [Abstract][Full Text] [Related]
19. The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology.
Stoyas CA; La Spada AR
Handb Clin Neurol; 2018; 147():143-170. PubMed ID: 29325609
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
